ACRV ▲ +0.6% - Acrivon Therapeutics, Inc.
$ACRV - Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKC? Inhibitor Preclinical Program from Aqilion AB
06-NOV-2026 08:00 AM ET
Share this post
More filings for $ACRV
ACRV ▲ +6.0% - Acrivon Therapeutics, Inc.Nov 4, 2026ACRV ▼ -1.1% - Acrivon Therapeutics, Inc.Oct 29, 2026ACRV ▲ +3.6% - Acrivon Therapeutics, Inc.Oct 20, 2026ACRV ▼ -0.5% - Acrivon Therapeutics, Inc.Sep 2, 2026ACRV ▲ +1.0% - Acrivon Therapeutics, Inc.Aug 31, 2026ACRV - Acrivon Therapeutics, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $ACRV filing history →💬 Comments
Loading comments…
Leave a comment